Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36: a Phase 1 Study
Phase of Trial: Phase I/II
Latest Information Update: 06 Oct 2015
At a glance
- Drugs Glucagon-like peptide-1 (Primary) ; Peptide YY 3-36 (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- 24 Sep 2010 Salcaprozate-sodium added as descriptor, as reported in an Emisphere Technologies media release.
- 24 Sep 2010 Results published in the American Journal of Clinical Nutrition, 18 August 2010, according to an Emisphere Technologies media release.
- 27 May 2009 Results have been reported in a media release from Emisphere Technologies.